Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 4/20 | 0.38 |
| ▸ | PGR | P06401 | 6/20 | 0.33 |
| ▸ | ENPP3 | O14638 | 2/20 | 0.33 |
| ▸ | ALPL | P05186 | 2/20 | 0.33 |
| ▸ | XIAP | P98170 | 2/20 | 0.33 |
| ▸ | RORC | P51449 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | IKBKB | O14920 | 1/20 | 0.31 |
| ▸ | IKBKE | Q14164 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | AR | P10275 | 1/20 | 0.31 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.31 |
| ▸ | SCN7A | Q01118 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4768286 | 0.87 | KCNH2 (0.36) | KCNH2PGRENPP3ALPLXIAP | |
| SCHEMBL14304003 | 0.86 | KCNH2 (0.49) | KCNH2PGRRORC | |
| SCHEMBL4716327 | 0.84 | ENPP3 (0.43) | KCNH2ENPP3ALPLXIAPRORC | |
| SCHEMBL14303592 | 0.78 | KCNH2 (0.44) | KCNH2ENPP3ALPLXIAPCYP3A4 | |
| SCHEMBL509554 | 0.77 | KCNH2 (0.52) | KCNH2PGRRORC | |
| SCHEMBL509286 | 0.76 | EPAS1 (0.40) | ENPP3ALPLXIAPCYP3A4AR | |
| SCHEMBL508348 | 0.76 | ENPP3 (0.45) | KCNH2ENPP3ALPLXIAPCYP3A4 | |
| SCHEMBL14540399 | 0.76 | ENPP3 (0.35) | KCNH2ENPP3ALPLXIAPRORC | |
| SCHEMBL14290740 | 0.76 | KCNH2 (0.36) | KCNH2PGRENPP3ALPLXIAP | |
| SCHEMBL508737 | 0.75 | KCNH2 (0.42) | KCNH2PGRRORC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1551828-B1 | PYRAZOLE DERIVATIVES | PFIZER LTD (GB) | 2008-01-23 | — | — | EP | disclosed |
| US-6933312-B2 | Pyrazole derivatives | AGOURON PHARMACEUTICALS, INC. (US) | 2005-08-23 | — | — | US | disclosed |
| US-20040133002-A1 | Pyrazole derivatives | PFIZER, INC. | 2004-07-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040133002-A1 | Pyrazole derivatives | REV1, RRS1, CYP2F1 | KCNH2 3181/4885PGR 942/4885ENPP3 1365/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.